Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $49.7600 (-1.21%) ($49.7600 - $49.7600) on Fri. Mar. 12, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.91% (three month average) | RSI | 62 | Latest Price | $49.7600(-1.21%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.9% a day on average for past five trading days. | Weekly Trend | TGTX advances 3.1% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(64%) ARKK(59%) IBB(59%) IWO(59%) | Factors Impacting TGTX price | TGTX will decline at least -1.955% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-19%) UNG(-2%) TLT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.955% (StdDev 3.91%) | Hourly BBV | 0.8 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $46.82(6.28%) | 10 Day Moving Average | $45.25(9.97%) | 20 Day Moving Average | $45.38(9.65%) | To recent high | -9.1% | To recent low | 19.4% | Market Cap | $6.302b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |